{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000028","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.435349+00:00","generated_at":"2026-05-14T23:21:10.745518+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Avalo Therapeutics Phase 2 LOTUS trial meets primary endpoint; HiSCR75 rates 42.2% and 42.9% for abdakibart in HS","bullets":["Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.","Statistically significant benefit on secondary endpoints HiSCR50, change in IHS4, and draining tunnel count.","Abdakibart well tolerated; most TEAEs mild to moderate, no neutropenia, serious infections, or opportunistic infections.","Response similar in patients with and without prior biologic exposure.","Avalo plans to advance abdakibart into a registrational Phase 3 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000028","json":"https://secwatch.observer/filing/0001534120-26-000028.json","markdown":"https://secwatch.observer/filing/0001534120-26-000028.md","text":"https://secwatch.observer/filing/0001534120-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/0001534120-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/avtx-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:21:10.745518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}